GT
MEDP icon

Glenmede Trust’s Medpace MEDP Stock Holding History

Glenmede Trust’s Portfolio MEDP Stock Details MEDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.17M Sell
4,512
-420
-9% -$215K 0.01% 561
2025
Q4 		$2.77M Buy
+4,932
New +$2.8M 0.01% 519
2025
Q1 		$13.2M Buy
43,222
+269
+0.6% +$90.5K 0.07% 284
2024
Q4 		$14.3M Buy
42,953
+22,708
+112% +$7.7M 0.07% 284
2024
Q3 		$6.76M Sell
20,245
-56,046
-73% -$21.3M 0.03% 409
2024
Q2 		$31.4M Buy
76,291
+27,655
+57% +$11M 0.16% 125
2024
Q1 		$19.7M Sell
48,636
-14,079
-22% -$4.95M 0.1% 209
2023
Q4 		$19.2M Sell
62,715
-474
-0.8% -$128K 0.1% 202
2023
Q3 		$15.3M Sell
63,189
-29,944
-32% -$7.66M 0.09% 236
2023
Q2 		$17.8M Buy
93,133
+172
+0.2% +$35.7K 0.1% 213
2023
Q1 		$17.5M Sell
92,961
-735
-0.8% -$152K 0.1% 217
2022
Q4 		$19.9M Sell
93,696
-13,125
-12% -$2.62M 0.12% 190
2022
Q3 		$16.8M Sell
106,821
-12,424
-10% -$1.98M 0.11% 210
2022
Q2 		$17.8M Buy
119,245
+113,707
+2,053% +$16.5M 0.1% 221
2022
Q1 		$905K Sell
5,538
-7,317
-57% -$1.21M ﹤0.01% 744
2021
Q4 		$2.8M Buy
12,855
+327
+3% +$68.5K 0.01% 507
2021
Q3 		$2.37M Buy
12,528
+18
+0.1% +$3.28K 0.01% 520
2021
Q2 		$2.21M Buy
12,510
+228
+2% +$39.4K 0.01% 522
2021
Q1 		$2.01M Sell
12,282
-925
-7% -$141K 0.01% 524
2020
Q4 		$1.84M Buy
13,207
+2,770
+27% +$349K 0.01% 534
2020
Q3 		$1.17M Sell
10,437
-2,395
-19% -$277K 0.01% 587
2020
Q2 		$1.19M Sell
12,832
-34,616
-73% -$2.95M 0.01% 573
2020
Q1 		$3.99M Hold
47,448
– – 0.02% 491
2019
Q4 		$3.99M Sell
47,448
-1,318
-3% -$102K 0.02% 491
2019
Q3 		$4.1K Buy
48,766
+107
+0.2% +$8.09K 0.02% 493
2019
Q2 		$3.18K Buy
48,659
+86
+0.2% +$4.96K 0.01% 558
2019
Q1 		$2.86K Buy
48,573
+3,120
+7% +$186K 0.01% 583
2018
Q4 		$2.4K Buy
45,453
+30,193
+198% +$1.66M 0.01% 591
2018
Q3 		$914K Buy
+15,260
New +$835K ﹤0.01% 765

Other funds holding MEDP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Glenmede Trust's MEDP Position: Q1 2026 in Review

Glenmede Trust reduced its Medpace (MEDP) stake by 8.5% in Q1 2026, selling an estimated $215K and leaving 4,512 shares worth $2.17M. The position accounts for 0.01% of the portfolio, ranked #561.

Glenmede Trust first reported a position in MEDP in Q3 2018 and has held it in 29 quarters since. The position peaked at $31.4M in Q2 2024. 729 funds tracked by Wall St. Rank hold MEDP as of Q1 2026.

  • Glenmede Trust held 4,512 shares of Medpace worth $2.17M as of Q1 2026.
  • Glenmede Trust sold 420 Medpace shares in Q1 2026, an estimated $215K.
  • Medpace made up 0.01% of Glenmede Trust's portfolio in Q1 2026, its #561 holding.
  • Glenmede Trust first reported a position in Medpace in Q3 2018 and has held it in 29 quarters since.
  • Glenmede Trust's Medpace position peaked at $31.4M in Q2 2024.
  • 729 funds tracked by Wall St. Rank held Medpace as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.